Abstract | BACKGROUND: The treatment of functional dyspepsia is controversial. AIM: The purpose of this paper is to clarify the initial effect of prokinetic, acid suppression and antianxiety treatment for functional dyspepsia patients. PATIENTS AND METHODS: RESULTS: Among 64 enrolled patients, 62 completed the study. Within 2 weeks, visual analogue scale score in the mosapride-treated group decreased from 2.29 +/-0.14 to 1.57 +/- 0.20; in the famotidine from 2.04 +/- 0.16 to 1.09 +/- 0.12 (mean +/- S.E.). Therefore, there were significant improvements of functional dyspepsia symptoms in mosapride- and famotidine-treated patients (P <0.01). Furthermore, famotidine was significantly more effective than mosapride (P < 0.05). On the contrary, visual analogue scale score in the tandospirone therapy was 2.23 +/- 0.20 and 2.13 +/- 0.22 before and at 2 weeks, respectively, without any significant improvement. CONCLUSIONS: A treatment regimen of famotidine at 40 mg/day had a significant favourable effect on the clinical outcome in functional dyspepsia patients.
|
Authors | H Seno, H Nakase, T Chiba |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 21 Suppl 2
Pg. 32-6
(Jun 2005)
ISSN: 0269-2813 [Print] England |
PMID | 15943844
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Anxiety Agents
- Benzamides
- Gastrointestinal Agents
- Isoindoles
- Morpholines
- Piperazines
- Pyrimidines
- Serotonin Receptor Agonists
- tandospirone
- Famotidine
- mosapride
|
Topics |
- Anti-Anxiety Agents
(therapeutic use)
- Anxiety Disorders
(drug therapy)
- Benzamides
(therapeutic use)
- Drug Therapy, Combination
- Dyspepsia
(drug therapy)
- Famotidine
(therapeutic use)
- Female
- Gastrointestinal Agents
(therapeutic use)
- Humans
- Isoindoles
- Male
- Middle Aged
- Morpholines
(therapeutic use)
- Piperazines
(therapeutic use)
- Pyrimidines
(therapeutic use)
- Serotonin Receptor Agonists
(therapeutic use)
|